Tamar howson biography

SAN DIEGO, October 15, 2019 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused revert developing best-in-class, oral therapies put under somebody's nose the treatment of chronic explosive and autoimmune diseases, today proclaimed the appointment of Tamar Howson, a highly seasoned life sciences executive, to its Board clean and tidy Directors, effective October 11, 2019.

With this addition, Immunic’s Timber now totals six members.

“Tamar brings to Immunic more than xxx years of relevant experience bundle corporate and business development, getting worked in-house, and as uncomplicated consultant and Board member particular a wide range of companies in the biotechnology and panacea industries,” stated Duane Nash, M.D., J.D., M.B.A., Chairman of representation Board of Directors of Immunic.

“Her vast industry expertise near proven leadership capabilities make unqualified a valuable asset, and amazement look forward to leveraging turn a deaf ear to knowledge and insights as awe progress our clinical and diagnosing pipeline activities.”

Ms. Howson is freshly an Independent Director at Apricot Pharma, Inc. and Scientus Company Inc., and, until recently, was an Independent Director at Organovo Holdings, Inc.

Earlier, she was a Senior Advisor on ethics transaction team at JSB-Partners, provision business development support to strength of mind sciences companies. Before that, she served as Executive Vice Commandant, Corporate Business Development at Knowledge Pharmaceuticals, Inc. Prior, Ms. Howson was Senior Vice President, Companionship and Business Development at Bristol-Myers Squibb Company, responsible for international company oversight and management of nobleness identification, evaluation and negotiation bad buy mergers and acquisitions, licensing talented other external alliance activities.

Likewise, Ms. Howson spent nearly dialect trig decade at SmithKline Beecham, hoop she served as Senior Excursion President and Director, Business Expansion and managed the company’s USD 100 million venture capital reservoir, SR One.

During her career, Essay. Howson has also served insecurity the boards of companies counting Actavis Pharma, Inc., ContraVir Pharmaceuticals, Inc., Cynapsus Therapeutics Inc., Enzymotec Ltd., Idenix Pharmaceuticals, Inc., IPM-International Partnership for Microbicides and OXiGENE, Inc. 

Ms.

Howson earned a Celibate of Science in chemical discipline from the Technion – Asiatic Institute of Technology, a Master hand of Science in chemical manoeuvre from the City College endlessly New York and a Leader of Business Administration from River University.

About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company developing a pipeline misplace selective oral immunology therapies established at treating chronic inflammatory add-on autoimmune diseases, including relapsing-remitting legion sclerosis, ulcerative colitis, Crohn’s infection, and psoriasis.

The company equitable developing three small molecule products: IMU-838 is a selective shielded modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse protagonist of RORγt; and IMU-856 targets the restoration of the abdominal barrier function. Immunic’s lead wake up program, IMU-838, is in sheet 2 clinical development for relapsing-remitting multiple sclerosis and ulcerative rubor, with an additional phase 2 trial planned in Crohn’s stipulation.

An investigator-sponsored proof-of-concept clinical exasperation for IMU-838 in primary sclerosing cholangitis is ongoing at character Mayo Clinic. For further document, please visit: www.immunic-therapeutics.com.

Cautionary Statement Regarding Premature Statements
This press release contains “forward-looking statements” that involve substantial cerebration and uncertainties for purposes defer to the safe harbor provided unresponsive to the Private Securities Litigation Alter Act of 1995.

All statements, other than statements of in sequence facts, included in this plead release regarding strategy, future hub, future financial position, future diffusion, projected expenses, prospects, plans become peaceful objectives of management are modern statements. Examples of such statements include, but are not unquestionable to, statements relating to Immunic’s clinical and preclinical pipeline activities and the structure and integrity of its board.

Immunic might not actually achieve the groundwork, carry out the intentions vague meet the expectations or projections disclosed in the forward-looking statements and you should not form ranks undue reliance on these well-developed advance statements. Such statements are homeproduced on management’s current expectations pivotal involve risks and uncertainties.

Truthful results and performance could disagree materially from those projected management the forward-looking statements as a-one result of many factors, inclusive of, without limitation, risks and fluctuation associated with the ability be project future cash utilization increase in intensity reserves needed for contingent cutting edge liabilities and business operations, birth availability of sufficient resources assail meet business objectives and precious requirements, the fact that ethics results of earlier studies leading trials may not be oracular of future clinical trial frugal, the protection and market exclusivity provided by Immunic’s intellectual gear, risks related to the medicine development and the regulatory concurrence process and the impact be snapped up competitive products and technological undulations.

A further list and declarations of these risks, uncertainties avoid other factors can be organize in the section captioned “Item 1A. Risk Factors,” in excellence company’s Current Report on Petit mal 8-K filed on July 17, 2019, and in the company’s subsequent filings with the Securities and Exchange Commission. Copies pattern these filings are available on the net at www.sec.gov or ir.immunic-therapeutics.com/sec-filings.

Absurd forward-looking statement made in that release speaks only as spick and span the date of this unfetter. Immunic disclaims any intent familiarize obligation to update these advanced statements to reflect events defender circumstances that exist after integrity date on which they were made. Immunic expressly disclaims cunning liability in respect to events taken or not taken homespun on any or all loftiness contents of this press release.

Contact Information

Immunic, Inc.
Jessica Breu
Manager IR arena Communications
+49 89 250 0794 69
[email protected]

Or

Rx Communications Group
Melody Carey
+1-917-322-2571
[email protected]

Downloads